EGFR and neoplasm: Furthermore, the 30% rate of EGFR testing before subsequent therapy is consistent with previous estimates (30–48%) [21–23] and emphasizes that, during the study period, a substantial proportion of patients initiated a subsequent therapy without updated information on the molecular profile of the tumor.